BAY 2927088
Alternative Names: BAY-2927088Latest Information Update: 03 Sep 2024
At a glance
- Originator Bayer; Broad Institute; Harvard University
- Developer Bayer
- Class Antineoplastics; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Non-small cell lung cancer
Most Recent Events
- 29 Aug 2024 BAY 2927088 receives Breakthrough Therapy status for Non-small cell lung cancer (Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in China
- 22 Aug 2024 Phase-III clinical trials in Non-small cell lung cancer (First-line therapy, Late-stage disease, Metastatic disease) in USA (PO) (NCT06452277)
- 28 Jun 2024 Bayer completes a phase I trial for Non-small Cell Lung Cancer (In volunteers) in USA(PO) (NCT06360211)